Skip to main content
An official website of the United States government
Principal Investigator
Augusto C. Ochoa
Awardee Organization

Lsu Health Sciences Center
United States

Fiscal Year
2025
Activity Code
UG1
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

Gulf South Clinical Trials Network (Gulf South NCORP)

The Gulf South Clinical Trials Network - NCORP (Gulf South -NCORP) and the Ochsner-Community-NCORP, the two NCORPs in Louisiana, have both met the objectives proposed for the last funding cycle, expanding access to and significantly increasing the number of patients participating in clinical trials in Louisiana and the Gulf South region. These successful NCORPs have agreed to come together to form the Gulf South NCORP, which will have as its primary affiliates the LSU – Cancer Center New Orleans (LSU-CC-New Orleans), LSU – Feist Weiller Cancer Center Shreveport (LSU-FWCC-Shreveport), Mary Bird Perkins Cancer Center (MBPCC) and the Ochsner-Cancer Center (Ochsner). The new Gulf South NCORP will provide cancer care and access to clinical trials for >50% of new cancer cases in the region, expand the number of sites offering access to clinical trials from 22 to 42 sites. The Gulf South NCORP will bring additional resources including the Louisiana Tumor SEER registry (LTR-SEER) and the state-wide cancer screening programs such as the Louisiana Breast and Cervical Health Program (LBCHP), and the Louisiana Comprehensive Cancer Control Program (LCCCP). In addition we will benefit from ongoing research led by our investigators. The new Gulf South NCORP has also expanded its network with major health providers in the region including the Veterans Administration Hospital (New Orleans), Woman’s Hospital (the largest dedicated clinical center for women’s health) in Baton Rouge and the Christus Health community sites. The new Gulf South NCORP has garnered the support of the Louisiana Department of Health Secretary and the Governor, who are developing a cancer care plan for the state (Taking Aim at Cancer in Louisiana Collaborative -TACL), where the Gulf South M/U CTN is the major provider of state-wide cancer clinical trials. This support will help us to continue increasing the participation of patients in NCORP and non-NCORP studies. To achieve our goals we will implement the following three strategies. 1. Expand the number of sites through additional partnerships with community organizations such as FQHC’s where we will test novel approaches to increase the participation of community physicians providing care to cancer patients in the region; 2. Support the development of research initiated by our investigators to understand the impact created by cancer in our region and 3. Increase our participation in national trials supported by NCORP and other organizations to expand the scope and depth of trials offered to our patients.

Publications

  • Borghaei H, Redman MW, Kelly K, Waqar SN, Robert F, Kiefer GJ, Stella PJ, Minichiello K, Gandara DR, Herbst RS, Papadimitrakopoulou VA. SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study). Clinical lung cancer. 2021 May;22(3):178-186. Epub 2020 Nov 10. PMID: 33358401
  • Henry NL, Unger JM, Schott AF, Fehrenbacher L, Flynn PJ, Prow DM, Sharer CW, Burton GV, Kuzma CS, Moseley A, Lew DL, Fisch MJ, Moinpour CM, Hershman DL, Wade JL 3rd. Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Feb 1;36(4):326-332. Epub 2017 Nov 14. PMID: 29136387
  • Durie BGM, Hoering A, Sexton R, Abidi MH, Epstein J, Rajkumar SV, Dispenzieri A, Kahanic SP, Thakuri MC, Reu FJ, Reynolds CM, Orlowski RZ, Barlogie B. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood cancer journal. 2020 May 11;10(5):53. PMID: 32393732
  • Puvvada SD, Stiff PJ, Leblanc M, Cook JR, Couban S, Leonard JP, Kahl B, Marcellus D, Shea TC, Winter JN, Li H, Rimsza LM, Friedberg JW, Smith SM. Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. British journal of haematology. 2016 Sep;174(5):686-91. Epub 2016 Apr 13. PMID: 27072903
  • Sadigh G, Duan F, An N, Gareen ID, Sicks J, Suga JM, Kehn H, Mehan PT, Bajaj R, Hanson DS, Dalia SM, Acoba JD, Yasar DG, Taylor MA, Park E, Wagner LI, Kircher SM, Carlos RC. Financial Hardship Among Patients With Early-Stage Colorectal Cancer. JAMA network open. 2024 Sep 3;7(9):e2431967. PMID: 39287948
  • Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara DR. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. The Lancet. Oncology. 2018 Jan;19(1):101-114. Epub 2017 Nov 20. PMID: 29169877
  • Flaig TW, Plets M, Hussain MHA, Agarwal N, Mitsiades N, Deshpande HA, Vaishampayan UN, Thompson IM Jr. Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA oncology. 2017 Nov 9;3(11):e170231. Epub 2017 Nov 9. PMID: 28358937
  • Moinpour CM, Unger JM, Ganz PA, Kornblith AB, Gaynor ER, Bowers MA, Gatti GS, Kaminski MS, Erba HP, Wang T, Yoon J, Press OW, Fisher RI. Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. Journal of cancer survivorship : research and practice. 2017 Feb;11(1):32-40. Epub 2016 Jul 12. PMID: 27405732
  • Heinrich MC, Rankin C, Blanke CD, Demetri GD, Borden EC, Ryan CW, von Mehren M, Blackstein ME, Priebat DA, Tap WD, Maki RG, Corless CL, Fletcher JA, Owzar K, Crowley JJ, Benjamin RS, Baker LH. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA oncology. 2017 Jul 1;3(7):944-952. PMID: 28196207
  • Kircher S, Duan F, An N, Gareen IF, Sicks JD, Sadigh G, Suga JM, Kehn H, Mehan PT, Bajaj R, Hanson DS, Dalia SM, Acoba JD, Yasar DG, Park ER, Wagner LI, Carlos RC. Patient-Reported Financial Burden of Treatment for Colon or Rectal Cancer. JAMA network open. 2024 Jan 2;7(1):e2350844. PMID: 38194233
  • Vaidya R, Unger JM, Loomba R, Hwang JP, Chugh R, Tincopa MA, Arnold KB, Hershman DL, Ramsey SD. Universal Viral Screening of Patients with Newly Diagnosed Cancer in the United States: A Cost-efficiency Evaluation. Cancer research communications. 2023 Sep 28;3(9):1959-1965. PMID: 37707388
  • Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R, Orlowski RZ, Barlogie B, Dispenzieri A. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet (London, England). 2017 Feb 4;389(10068):519-527. Epub 2016 Dec 23. PMID: 28017406